Related Experiment Video

Updated: Jun 10, 2026

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

How can we tell if PET imaging for cancer is cost effective?

Michael P Mac Manus, Rodney J Hicks

    The Lancet. Oncology
    |August 7, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
    09:18

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

    Published on: February 3, 2026

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
    08:55

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

    Published on: November 2, 2014

    Related Experiment Videos

    Last Updated: Jun 10, 2026

    Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
    08:45

    Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

    Published on: November 13, 2012

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
    09:18

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

    Published on: February 3, 2026

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
    08:55

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

    Published on: November 2, 2014

    Related Concept Videos

    Positron Emission Tomography01:29

    Positron Emission Tomography

    Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
    One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
    Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

    Imaging Studies II: Positron Emission Tomography and Scintigraphy

    Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
    Fundamental Principles of PET

    Articles linked to this work by shared authors, journal, and citation graph.

    Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

    Whole genome and exome sequencing of pancreatic neuroendocrine tumour to investigate PRRT response.

    Endocrine-related cancer·2026

    Optimal Imaging Strategies After Negative PSMA PET/CT Results in Patients With Prostate Cancer Biochemical Recurrence: AJR Expert Panel Narrative Review.

    AJR. American journal of roentgenology·2026

    Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

    The Lancet. Oncology·2026

    [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

    The Lancet. Oncology·2026

    Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.

    The Lancet. Oncology·2026

    Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

    The Lancet. Oncology·2026

    Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

    The Lancet. Oncology·2026

    An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

    The Lancet. Oncology·2026

    Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

    The Lancet. Oncology·2026

    Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

    The Lancet. Oncology·2026

    Lactate-induced epithelial-mesenchymal transition: a metabolic nexus in pancreatic cancer metastasis.

    Translational cancer research·2026

    Hypoxia-inducible factor-1α promotes the malignant progression of cervical cancer cells by regulating lactate dehydrogenase A-mediated glycolysis.

    Translational cancer research·2026

    Feasibility, reliability, and clinical value of genomic assay on pre-therapeutic biopsy for endocrine receptor-positive HER2-negative early breast cancer.

    Frontiers in oncology·2026

    Conventional chest CT features are associated with Ki-67 labeling index in lung adenocarcinoma: a single-center retrospective radiopathologic study.

    Journal of thoracic disease·2026

    Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation.

    Frontiers in oncology·2026

    Diagnosing lung cancer invading the pulmonary artery using ultra-low-dose CT pulmonary angiography: a feasibility study.

    Journal of thoracic disease·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us